Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 21;61(4):764.
doi: 10.3390/medicina61040764.

Use of Quadruple Therapy in the Management of Hypertension: A Systematic Review of Randomized Controlled Trials

Affiliations

Use of Quadruple Therapy in the Management of Hypertension: A Systematic Review of Randomized Controlled Trials

Khalid A Alnemer. Medicina (Kaunas). .

Abstract

Background and objectives: Hypertension remains a leading global cause of cardiovascular morbidity and mortality, with suboptimal blood pressure (BP) control despite available treatments. Monotherapy often fails to achieve target BP, necessitating combination therapies. Quadruple low-dose combination therapy (quadpill) has emerged as a potential strategy to enhance efficacy while minimizing side effects. This systematic review evaluates the effectiveness and safety of quadpill therapy compared to standard monotherapy and dual therapy. Methods: A systematic search was conducted in PubMed, Web of Science, and Scopus from inception till January 2025 for randomized controlled trials (RCTs) investigating quadruple therapy in hypertensive patients. Studies comparing quadpill therapy with monotherapy, dual therapy, or placebo were included. Data on BP reduction, achievement of target BP, and adverse events were extracted and analyzed. The Cochrane Risk of Bias tool (RoB-2) was used to assess study quality. Results: Five RCTs were included in the current systematic review. Quadpill therapy resulted in greater reductions in systolic BP (SBP and diastolic BP (DBP) compared to monotherapy and dual therapy across all time points. The proportion of patients achieving target BP (<140/90 mmHg) was significantly higher in the quadpill group. The safety profile was favorable, with adverse event rates comparable to those in monotherapy and dual therapy groups. Notable adverse effects included mild dizziness, edema, and biochemical alterations (elevated fasting glucose and uric acid levels), but these did not lead to significant treatment discontinuation. Conclusions: Quadruple low-dose combination therapy is a promising approach for improving BP control while maintaining a favorable safety profile. Early initiation of quadpill therapy could mitigate treatment inertia and improve long-term cardiovascular outcomes.

Keywords: combination; diastolic blood pressure; hypertension; quadruple; systolic blood pressure.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram of searching and screening.
Figure 2
Figure 2
Risk of bias assessment of RCTs using Rob-2 [16,21,26,27,28].

Similar articles

References

    1. Unger T., Borghi C., Charchar F., Khan N.A., Poulter N.R., Prabhakaran D., Ramirez A., Schlaich M., Stergiou G.S., Tomaszewski M., et al. 2020 International Society of Hypertension global hypertension practice guidelines. J. Hypertens. 2020;38:982–1004. doi: 10.1097/HJH.0000000000002453. (In English) - DOI - PubMed
    1. Liu L.-S. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J. Geriatr. Cardiol. 2019;16:182–241. doi: 10.11909/j.issn.1671-5411.2019.03.014. (In English) - DOI - PMC - PubMed
    1. GBD 2019 Risk Factors Collaborators Global burden of 87 risk factors in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1223–1249. doi: 10.1016/S0140-6736(20)30752-2. (In English) - DOI - PMC - PubMed
    1. Lu J., Lu Y., Wang X., Li X., Linderman G.C., Wu C., Cheng X., Mu L., Zhang H., Liu J., et al. Prevalence, awareness, treatment, and control of hypertension in China: Data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project) Lancet. 2017;390:2549–2558. doi: 10.1016/S0140-6736(17)32478-9. (In English) - DOI - PubMed
    1. McEvoy J.W., McCarthy C.P., Bruno R.M., Brouwers S., Canavan M.D., Ceconi C., Christodorescu R.M., Daskalopoulou S.S., Ferro C.J., Gerdts E., et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur. Heart J. 2024;45:3912–4018. doi: 10.1093/eurheartj/ehae178. (In English) - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources